Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients

Acta Haematologica

Volumn 128, Issue 2, 2012, Pages 113-118

  Cancado, Rodolfo ^a,b   Olivato, Maria Cristina A ^a   Bruniera, Paula ^a   Szarf, Gilberto ^a   De Moraes Bastos, Roberto ^a   Rezende Melo, Murilo ^a   Chiattone, Carlos ^a  

^a FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^b Cançado Hemocentro da Santa Casa de São Paulo Rua Marquêcs de Itú ^*  (Brazil)

Author keywords

Blood transfusion; Deferasirox; Iron overload; Oral chelation therapy; Sickle cell anemia

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; DEFERASIROX; FERRITIN; IRON;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FERRITIN BLOOD LEVEL; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; KIDNEY FAILURE; MALE; NAUSEA; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA MAJOR; TREATMENT DURATION;

ADOLESCENT; ADULT; ANEMIA, SICKLE CELL; BENZOIC ACIDS; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; PROSPECTIVE STUDIES; TRIAZOLES; YOUNG ADULT;

EID: 84863099186     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000338560     Document Type: Article

References (24)

1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Abboud M, Gallagher G, Kutlar A, Nichols FT, Bonds DR, Brambilla D: Prevention of a first stroke by transfusions in children with sickle cell anaemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998; 339: 5-11. (Pubitemid 28304491)
2. National Institutes of Health: Management and therapy of sickle cell disease. National Heart, Lung, and Blood Institute. 2002. http:www.nhibi.nih. gov.
3. Vichinsky EP, Ohene-Frempong K: Transfusion Committee. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey. Pediatr Hematol Oncol 2011; 28: 37-42.
4. Gabutti V, Piga A: Results of long-term ironchelating therapy. Acta Haematol 1996; 95: 26-36.
5. Ballas SK: Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38(suppl 1):30-36. (Pubitemid 32110270)
6. Manci EA, Culberson DE, Yang YM, Gardner TM, Powell R, Haynes J Jr, Shah AK, Mankad VN, Investigators of the Cooperative Study of Sickle Cell Disease: Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003; 123: 359-365.
7. Inati A: Recent advances in improving the management of sickle cell disease. Blood Rev 2009; 23(suppl 1):S9-S13.
8. Lobo C, Angulo IL, Aparicio LR, Drelichman GI, Zanichelli MA, Cancado R, on behalf of the RELATH investigators: Retrospective epidemiological study of Latin American patients with transfusional hemosiderosis: the first Latin American epidemiological study in iron overload-the RELATH study. Hematology 2011; 16: 265-273.
9. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW: Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 1994; 331: 567-573. (Pubitemid 24265698)
10. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR: Survival in medically treated patients with homozygous-thalassaemia major. N Engl J Med 1994; 331: 574-578. (Pubitemid 24265699)
11. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gatterman N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A, EPIC Study Investigators: Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1,744 patients with transfusion-dependent anaemias. Haematologica 2010; 95: 557-566.
12. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok K, Kattamis A, Klinic Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Ressayre-Djaffer C, Marios P, Alberti D: A phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with-thalassemia. Blood 2006; 107: 3455-3462.
13. Vichinsky E, Bernaudin F, Forni GL, Garnder R, Hassell K, Henney MM, Inusa B, Kutlar AB, Lane P, Mathias L, Porter J, Tebbi C, Wilson F, Griffel L, Deng W, Giannone V, Coates T: Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol 2011; 154: 387-397.
14. Gandon Y, Olivié D, Guyader D, Aubé C, Oberti F, Sebille V, Deugnier Y: Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-362. (Pubitemid 38169542)
15. Anderson LJ, Holden S, Davies B, Prescott E, Charrier C, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ: Cardiovascular T2-star (T2 * ) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179. (Pubitemid 33139463)
16. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ: A single breath-hold multiecho T2 * cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18: 33-39. (Pubitemid 36791266)
17. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ, STOP Investigators: Impact of chronic transfusion on incidende of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anaemia. J Pediatr 2001; 139: 785-789. (Pubitemid 34014456)
18. Fung EB, Harmatz P, Milet M, Ballas SK, De Castro L, Hagar W, Owen W, Olivieri N, Smith-Whitley K, Darbari D, Wang W, Vichinsky E, Multi-Center Iron Overload Research Group: Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. Am J Hematol 2007; 82: 255-265. (Pubitemid 46564319)
19. Wood JC: Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol 2007; 14: 183-190. (Pubitemid 46597601)
20. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, McClelland RA, Liu PP, Templeton DM, Koren G: Iron-chelation therapy with oral deferiprone in patients with thalassaemia major. N Engl J Med 1995; 332: 918-922.
21. Brittenham GM, Cohen AR, McLaren CE, Martin MB, Griffith PM, Nienhuis AW, Young NS, Allen CJ, Farrell DE, Harris JW: Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anaemia and thalassemia major. Am J Hematol 2003; 42: 81-85.
22. Pennell D, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Ydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubeert B, Taher A: Deferasirox for up to 3 years leads to continued improvement of myocardial T2 * in patients with beta-thalassemia major. Haematologica DOI:10.3324/haematol.2011.049957.
23. Galanello R, Piga A, Forni GL, Bertrand Y, Foschini ML, Bordone E, Leoni G, Kavagetto A, Zappu A, Longo F, Maseruka H, Hewson N, Sechaud R, Belleli R, Albert D: Phase II clinical evaluation of deferasirox, a oncedaily oral chelating agent, in pediatric patients with-thalassaemia major. Haematologica 2006; 91: 1343-1351. (Pubitemid 44569807)
24. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto Z, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Albert D: Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxiamine in thalassaemia patients with transfusional iron overload. Haematologica 2006; 91: 873-880. (Pubitemid 44023139)